Aequus Pharmaceuticals (CVE:AQS) Trading Up 100%

Aequus Pharmaceuticals Inc. (CVE:AQS) shot up 100% during trading on Wednesday . The company traded as high as C$0.04 and last traded at C$0.04. 420,800 shares traded hands during mid-day trading, an increase of 103% from the average session volume of 206,982 shares. The stock had previously closed at C$0.02.

Aequus Pharmaceuticals Stock Performance

The firm has a fifty day simple moving average of C$0.02 and a 200 day simple moving average of C$0.02. The company has a debt-to-equity ratio of 138.88, a current ratio of 0.09 and a quick ratio of 0.46. The company has a market cap of C$5.31 million, a price-to-earnings ratio of -1.50 and a beta of 0.17.

Aequus Pharmaceuticals (CVE:AQS) last announced its earnings results on Monday, April 29th. The company reported C($0.01) earnings per share for the quarter. The company had revenue of C$0.05 million during the quarter. On average, sell-side analysts expect that Aequus Pharmaceuticals Inc. will post -0.1 earnings per share for the current fiscal year.

Aequus Pharmaceuticals Company Profile

Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.